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BACKGROUND: The T helper 17 (Th17) cells recently identified as distinct T helper cell lineage are characterised by their production of
the proinflammatory cytokine interleukin 17. Although much effort has been made in understanding the function of Th17 cells in the
pathogenesis of different diseases, their influence in carcinogenesis remain largely unknown.
METHODS: We studied the prevalence and induction of Th17 cells in head and neck squamous cell carcinoma (HNSCC) patients by
flow cytometry. To determine the migration mechanism of Th17 cells into primary tumours and metastasis of HNSCC, we
performed chemotaxis assays. We analysed the proliferation and the angiogenesis-related proteins of HNSCCs in the presence of
Th17 cells with MTT-based proliferation assay and an angiogenesis protein array.
RESULTS: In this study, we showed that the prevalence of Th17 cells is elevated in peripheral blood of HNSCC patients. In addition,
tumour tissue and tumour-draining lymph nodes are infiltrated by a huge number of Th17 cells representing an important fraction of
the tumour-infiltrating lymphocytes (TILs). We further showed that Th17 cells can be induced and expanded in tumour
microenvironment through cytokines produced by tumour cells and TILs, and in addition can be recruited to the tumour milieu
through a CCR6/CCL20-dependent mechanism. Furthermore, we showed that the proliferation and angiogenesis of HNSCC are
impaired in the presence of Th17 cells.
CONCLUSION: We conclude that Th17 cells have a substantial impact on the carcinogenesis of HNSCCs and on their metastasis and
could serve as a potential therapeutic target to modulate anti-tumour response in HNSCC.
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T helper 17 (Th17) cells are proinflammatory CD4þ effector T
helper cells, which produce the cytokine interleukin 17 (IL-17).
This distinct T helper cell lineage was discovered 5 years ago
(Harrington et al, 2005) and have a prominent function in mucosal
immunity and autoimmune diseases such as multiple sclerosis, as
well as human inflammatory bowel disease and psoriasis. Aside
from secreting IL-17A, human Th17 cells produce the cytokines
IL-17F, -21, -22 and -26, and express the surface receptors CD161,
CCR6, IL-23R (Cosmi et al, 2008; Singh et al, 2008) and the orphan
nuclear receptor ROR2C (Ivanov et al, 2006). In addition to Th17
cells, there are subpopulations of CD8þ T cells, gd cells and NKT
cells able to produce IL-17 (Coquet et al, 2008; Lee et al, 2008;
Rachitskaya et al, 2008; Roark et al, 2008; Kondo et al, 2009;
O’Brien et al, 2009). The secretion of IL-17 leads to the induction
of chemokines, matrix metalloproteinases and antimicrobial
peptides in surrounding tissue cells, leading to inflammation
and the recruitment of neutrophils and macrophages (Martinez
et al, 2008). The differentiation of Th17 cells in human beings is
induced through the cytokines IL-1b and -6 (Acosta-Rodriguez
et al, 2007) and requires the transcription factor ROR2C (Ivanov
et al, 2006); their expansion is regulated by IL-23 (Chizzolini et al,
2008). Several cytokines, including type I and type II interferon,
IL-2, -4, -12 and -27 inhibit Th17 differentiation (Diveu et al, 2009).
The Th17 cells are an ambitious field in current immunology
research, but less is known about the function of Th17 cells in
cancer development, particularly nothing is known about the Th17
lineage in head and neck squamous cell carcinomas (HNSCCs).
Head and neck cancer is an aggressive malignancy comprising
about 6% of all new diagnosed cancers (Liu et al, 2009). A total of
95% of tumours arising in the head and neck region are squamous
cell carcinomas. The HNSCCs are most commonly associated with
smoking and alcohol abuse (Uppaluri et al, 2008). Despite
advances in surgery, radio- and chemotherapy, HNSCC patients
have a poor prognosis because of a high recurrence rate
(Braakhuis et al, 2005). Although it was shown that HNSCCs are
infiltrated by a high number of various species of tumour-
infiltrating lymphocytes (TILs) (Uppaluri et al, 2008), these are not
capable to eradicate the tumour as a result of evolving multiple
mechanisms for tumour immune evasion by HNSCC tumours
and deranging of the functions of TILs in HNSCC patients. It is
assumed that HNSCCs produce various immunosuppressive and
tumour-promoting cytokines, which leads to the impaired anti-
tumour response (Pries and Wollenberg, 2006); however, the exact
mechanisms, which leads to these immunomodulations, remain
mostly unknown (Chin et al, 2004) and are discussed highly
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scontroversial. In addition, it is hypothesised that tumour cells
develop mechanisms to evade growth inhibitory effects of
cytokines that are present in the tumour microenvironment. It is
well established that inflammation is closely connected to HNSCC
development (Douglas et al, 2004), because of the induction of
chronic inflammation caused by exposure to irritants in inhaled
air, especially cigarette smoke, which enhance the nidation of
viruses and airborne microbes and therewith promote tumour
growth. In consideration of these facts, we propose a high impact
of the proinflammatory Th17 cells on HNSCC pathogenesis and
anti-tumour response.
In our study, we revealed that HNSCC patients have elevated
levels of Th17 cells in their peripheral blood compared with
healthy controls. In addition, huge numbers of Th17 cells infiltrate
primary tumours as well as lymph node metastasis of head and
neck cancer. We could identify the HNSCC microenvironment as a
strong Th17 cell inducer. Further, we could show for the first time
that Th17 cells actively migrate to the HNSCC tumour milieu and
have a functional impact on tumour proliferation and angiogenesis
in human beings.
MATERIALS AND METHODS
Samples
Peripheral blood was obtained from HNSCC patients (n¼25,
age¼52–72 years, mean 62 years) and as controls from healthy
individuals (n¼25). All donors participated on a voluntary basis
and gave written informed consent. This study was conducted
according to the principles expressed in the Declaration of
Helsinki and was approved by the local ethics committee. Tumour
tissue (n¼10) and metastatic lymph nodes (n¼20) were obtained
from head and neck cancer patients undergoing head and neck
surgery. For HNSCC samples, patients with a known history of
HNSCC were enrolled and malignancy was assessed by a patho-
logical examination of the biopsies. Patients included in the study
had not yet received any chemo- or radiotherapy.
Isolation of T cells and Th17 cells
The PBMCs were isolated from freshly derived peripheral blood by
centrifugation on a Ficoll Hypaque density gradient (PAA
Laboratories, Pasching, Austria). The CD4þ cells were enriched
by negative selection using a CD4 T cell isolation kit II (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the manufac-
turer’s instructions. The purity of T cells was 490% determined by
flow cytometry. The Th17 cells were purified using an IL-17
Secretion Assay-Cell Enrichment and Detection kit (Miltenyi
Biotec) according to the manufacturer’s instructions and a postsort
with an FACS Aria (BD Biosciences, Heidelberg, Germany). We
revealed a purity of 98% gated on PI-negative cells.
Cell culture and tumour supernatants
The permanent HNSCC cell lines, Pittsburgh Cancer Institute-1
(PCI-1), PCI-13 (generously given to us by Theresa Whiteside,
Pittsburgh Cancer Institute) and BHY, were cultured in DMEM
(PAA Laboratories) supplemented with 10% heat-inactivated FCS,
1% non-essential amino acids and 1% sodium pyruvate (PAA
Laboratories) under standard culture conditions (371C, 5% CO2).
Tumour supernatants of these cell lines were collected 48h after
medium exchange and were immediately cryopreserved and stored
in liquid nitrogen. The PBMCs and T cells were cultured in
RPMI1640 (PAA Laboratories) supplemented with 100Uml
–1
penicillin, 0.1mgml
–1 Streptomycin, 0.3mgml
–1 L-glutamine
(Sigma-Aldrich, Steinheim, Germany) and 10% human AB serum
(PAA Laboratories) in 96-well plates (Nunc, Langenselbold,
Germany) at 5 10
4 cells per well.
Single cell suspensions
Freshly derived tumour tissue or tumour-draining lymph node
(TDLN) tissue was minced into very small pieces and washed
in PBS. The tissue was digested in DMEM supplemented with
300Uml
–1 collagenase and 100Uml
–1 hyaluronidase (Sigma-
Aldrich) for 2h at 371C under permanent rotating. Afterwards,
the suspension was washed in PBS and resuspended in DMEM
supplemented with 5mgml
–1dispase (Sigma-Aldrich) for 60min.
The cell suspension was filtrated through a 100mm filter to obtain
the single cell suspension. For cytokine analysis, 10mgml
–1
Brefeldin A (Sigma-Aldrich) was added during all steps of
incubation.
Th17 cell induction
For the induction of Th17 cells, isolated CD4þ T cells were
stimulated with 5mgml
–1 CD3 (OKT3) and 1mgml
–1 CD28
(CD28.2) antibody (BD Biosciences) in RPMI1640 with 50Uml
–1
IL-2 (eBioscience, Cambridge, UK) in 48-well plates (Nunc). The T
cells were either cultured with tumour supernatants from HNSCC
cell lines or from single cell suspensions of tumour or TDLN tissue
or with IL-1b (10ngml
–1), IL-6 (20ngml
–1), IL-23 (10ngml
–1)o r
medium alone. On day 7, the T cells were harvested, stained for
flow cytometry analysis to quantify the induction of Th17 cells. For
blocking experiments, blocking antibodies for IL-1b, -6, -23 and
prostaglandin E(2) (PGE(2)) (R&D, 5mlml
–1) were added to the
Th17 cells during incubation.
Antibodies
Monoclonal antibodies (mAbs) were purchased from Becton
Dickinson except for anti-human IL-17A, IL-22, CCR6, IL-17R,
IL-21R, IL-22R antibodies obtained from R&D (Minneapolis, MN,
USA) and anti-human CD27, IL-17A, -23 and RORgt obtained
from eBioscience. All mAbs were used according to the
manufacturer’s recommendations.
Flow cytometry
Before intracellular staining, T cells were restimulated for 4h with
50ngml
–1phorbol 12-myristate 13-acetate (PMA) and 100ngml
–1
ionomycin (Sigma-Aldrich) in the presence of 10mgml
–1Brefeldin
A. The cells were analysed on an FACS Canto A flow cytometer
(BD Biosciences) with FACS Diva software 6.0 and evaluated with
FlowJo software (TreeStar, Ashland, OR, USA). The T cells were
surface stained according to standard protocols. Briefly, T cells
were washed three times in FACS buffer (PBS supplemented with
1% BSA and 0.1% sodiumazide) and stained with fluorescent-
labelled mAbs for 20min at 41C. For intracellular staining, cells
were fixed and permeabilised with the Flow Cytometry Fixation and
Permeabilisation Buffer kit (R&D) according to manufacturer’s
protocol and subsequently intracellularly stained. Fluorescent-
labelled isotype controls (BD Biosciences) or fluorescence-minus-
one controls were used in all experiments to determine background
fluorescence and exclude unspecific binding. Doublets of cells were
excluded in the analysis, as well as dead cells, which were excluded
by Annexin V/PI staining (BD Biosciences). In case of the usage of
unstained primary antibodies (IL-23), a control with secondary
antibody without primary antibody was performed to detect
unspecific binding of the secondary antibody.
ELISA and multiplex cytokine assay (Luminex)
Secreted IL-23 was measured with the human IL-23(p19/p40)
ELISA Ready-SET-Go! kit from eBioscience according to the
manufacturer’s protocol. Multiplex immunoanalytic xMAP tech-
nology was used for the measurement of cytokines in tumour
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ssupernatants. Samples were cryopreserved and stored in liquid
nitrogen. Directly before analysis, the aliquots were thawed slowly
on ice. Commercially available cytokine kits (Bio-Rad Labora-
tories, Munich, Germany) were used. The measurement was
performed with the Bioplex 200 system and Bioplex manager
software (Bio-Rad Laboratories). The analysis and preparation
were performed according to the manufacturer’s instructions.
Immunofluorescence
Tumour tissue was embedded in Shandon Cryochrome (Thermo
Electron Corporation, Pittsburgh, PA, USA) and maintained in
liquid nitrogen. The tissue was cut into 6mm sections. The slides
were fixed in ice-cold acetone for 10min, air dried and washed
in TBS (Bio-Rad Laboratories). The sections were incubated in
Ultra Block (LabVision, Fremont, CA, USA) for 30min to diminish
unspecific binding. The primary mAbs mouse anti-human CD4
[1:100] and goat anti-human IL-17 [1:50] were diluted in staining
buffer (TBS supplemented with 1% Ultra Block) and the sections
were incubated overnight at 41C in a humidified chamber.
After three washing steps with TBS, secondary antibodies (Alexa
Fluor 350-conjugated rabbit anti-goat IgG [1:100] (Invitrogen,
Karlsruhe, Germany) and Cy2-conjugated rabbit anti-mouse IgG
[1:400] (Dianova, Hamburg, Germany)) diluted in staining buffer
were added for 1h. The slides were counterstained with PI
(10mlml
–1) for 3min at room temperature. Isotype controls were
performed for each antibody. The sections were visualised using a
Zeiss Axiovert 200M fluorescence microscope equipped with an
Apoptome and Zeiss Axio Vision Software (Zeiss, Go ¨ttingen,
Germany).
Proliferation assay
The proliferation of tumour cells was determined with an MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay (Sigma-Aldrich) according to the manufacturer’s instruc-
tions and was evaluated with an iMark Microplate Absorbance
Reader (Bio-Rad Laboratories).
Migration assay
The migration of Th17 cells was studied performing a chemotaxis
assay using a ChemoTx 96-well chamber with 5mm pore size
(Neuroprobe Inc., Gaithersburg, MD, USA) and quantitated by
flow cytometry. The wells of the ChemoTx plate were filled either
with serum-free media or freshly derived single cell suspensions of
tumour or TDLN tissue suspended in serum-free media. Isolated
Th17 cells were transferred onto the filter of the chemotaxis
chamber. The chamber was incubated for 7h at 371C. After
incubation, the non-migrated cells were flushed with PBS and the
number of migrated Th17 cells in the wells was determined. To
block CCR6, a CCR6 blocking antibody (R&D, 5mlml
–1) was
added to the cell suspensions 30min before incubation of the
chemotaxis assay.
Angiogenesis/vasculogenesis protein array
The HNSCC cell line PCI-13 was incubated with isolated Th17 cells
or PBMCs depleted from Th17 cells for 48h. Afterwards, the
protein of the tumour cells was isolated. Briefly, cells were scraped
from the tissue culture flask and resuspended in lysis buffer
(1% NP-40, 20mM Tris–HCl (pH 8.0), 137mM NaCl, 10% glycerol,
2m M EDTA, 10mgml
–1 Aprotinin, 10mgml
–1 Leupeptin). After
45min of incubation on ice, the suspension was centrifuged, the
supernatant decanted and the amount of protein was measured
photometrically. Angiogenesis-related protein expression was
examined with the human angiogenesis antibody array (R&D)
according to the manufacturer’s protocol. The data was evaluated
with the Quantity One software (Bio-Rad Laboratories) by
quantifying the mean spot pixel densities.
Statistical analysis
Standard two-tailed Student’s t-tests were used for statistical
analysis with P-values p 0.05 considered significant. Significant
data sets are labelled with an asterisk (*). We evaluated the
statistics with SPSS Statistics software (SPSS GmbH Software,
Munich, Germany).
RESULTS
The level of Th17 cells is elevated in peripheral blood of
HNSCC patients
To address the issue whether there is a disturbed prevalence of
Th17 cells in head and neck cancer patients, we first analysed the
prevalence of Th17 cells in peripheral blood of HNSCC patients
compared with healthy controls. The PBMCs were isolated and
restimulated with PMA and ionomycin for 4h in the presence of
Brefeldin A and Th17 cells were quantified by flow cytometry. The
Th17 cells were identified as CD3þCD4þIL-17þ cell population.
As shown in Figure 1A, there was a statistically significant higher
10
12
14
16
18
20
0
2
4
6
8
%
 
o
f
 
T
h
1
7
 
c
e
l
l
s
%
 
o
f
 
T
h
1
7
/
T
h
1
 
c
e
l
l
s
HNSCC Healthy HNSCC Healthy
0.5
0.6
0.7
0.8
0.1
0.2
0.3
0.4
0
Figure 1 Prevalence of Th17 and Th1/Th17 cells in peripheral blood of HNSCC patients. The CD4þ T cells were isolated from peripheral blood of
HNSCC patients and healthy controls and subsequently incubated for 4h in the presence of PMA/Ionomycin and Brefeldin A. The cells were stained with
CD3-FITC, CD4-PerCP, IL-17-APC, ROR2C-PE and IFNg-PECy7 and analysed by flow cytometry. The CD3 and CD4þ T cells were gated in the FACS
analysis. (A) Comparison of the prevalence of Th17 cells in peripheral blood of healthy persons (n¼25) and HNSCC patients (n¼25) with Po0.05. The
data is expressed as the frequency of Th17 cells in the lymphocyte population. The box plots show the median (middle line), 25th and 75th percentiles
(box), the extreme values (whiskers, which indicate the 90th and 10th percentile) and the outliers (circles). (B) Prevalence of Th17/Th1 cells in peripheral
blood of head and neck cancer patients (n¼25) compared with healthy controls (n¼25) with Po0.05. The data is expressed as the frequency of Th17/Th1
cells in the Th17 population.
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spercentage of Th17 cells in peripheral blood of cancer patients
(0.4568±0.0319%, n¼25) compared with healthy controls
(0.1574±0.0272%, n¼25) with Po0.01.
Th1/Th17 cells are decreased in peripheral blood
of HNSCC patients
Th1/Th17 cells, which simultaneously produce the Th17 cytokine
IL-17 and the Th1 cytokine IFNg, account for approximately
10% of the whole Th17 cell population in healthy individuals
(11.33±1.437%). In peripheral blood of HNSCC patients,
this subpopulation is significantly decreased (1.14±1.113%) with
Po0.05 (Figure 1B). We identified the Th1/Th17 cells as the
CD3þCD4þIL-17þIFNgþ population.
Tumour tissue and TDLNs are infiltrated by a huge
number of Th17 cells
Next, we determined the amount of Th17 cells infiltrating tumours
and metastatic lymph nodes of head and neck cancer. In 100% of
the TDLNs, we could identify a high proportion of CD4þIL17þ
cells (0.2345±0.0584% of all TILs) (Figure 2A and B). We could
also detect Th17 cells in primary HNSCCs of all locations
(0.8467±3.567% of all TILs and 10.65%±3.567 of all T cells)
except for larynx carcinomas, which were sparely infiltrated by
lymphocytes and so we were not able to detect a definite Th17 cell
population. To affirm that these Th17 cells actually secrete IL-17 in
tumour milieu, we measured the IL-17 concentration from tumour
supernatants derived from tumour single cell suspensions by
ELISA. Indeed, we measured an IL-17 concentration of 512±175
pgml
–1 (n¼10) (data not shown).
Th17 cell inducing cytokines IL-1b, -6 and -23 are
present in HNSCC tumour milieu
We investigated whether the increased prevalence of Th17 cells in
tumours and TDLNs is caused by an induction of Th17 cells or
by the migration of Th17 cells towards the tumour site. The
differentiation of Th17 cells in human beings is initiated and
regulated by the cytokines IL-1b and -6 and their maintenance by
IL-23 (Romagnani et al, 2009). Thus, to examine the first
hypothesis, we determined the existence of these cytokines in
HNSCC tumour milieu. The cytokines in tumour supernatants
were determined with ELISA and multiplex assays. We found that
HNSCC cell lines secrete the cytokines IL-6 and -23, but not IL-1b.
In tumour supernatants of freshly derived tumours and TDLNs, we
could detect all three cytokines IL-1b, -6 and -23 (data not shown).
To evaluate which type of cells from the single cell suspensions
secrete the corresponding cytokine, we determined the cytokines
also directly in ex vivo derived tumour cells and tumour-
infiltrating cells by flow cytometry. The tumour cells secrete the
cytokines IL-23 (99%) and IL-6 (99%). The IL-1b is secreted only
by TILs (26%), which produce IL-23 (29%) and IL-6 (32%) as well
(Figure 3A).
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Figure 2 Identification of Th17 cells in primary tumours and TDLNs of HNSCC patients. Tumour and lymph node tissues were enzymatically digested to
obtain single cells suspension. These cells were stained with CD3-FITC, CD4-PerCP, IL-17-APC and ROR2C-PE analysed by flow cytometry. (A) Frequency
of the Th17 cells in primary tumours (n¼10) and lymph node metastasis (n¼15). The box plots show the median (middle line), 25th and 75th percentiles
(box), the extreme values (whiskers, which indicate the 90th and 10th percentile) and the outliers (circles). (B) Flow cytometric analysis of tumour-derived
Th17 cells for their CD107a expression. The cells were stained with CD107a- FITC, CD3-APC Cy7, CD4-PerCP, IL-17-APC. (C) Immunhistochemical
staining of tumour and TDLN tissue. The Th17 cells were stained with mAbs against IL-17 (secondary conjugated with AlexaFluor 350) and against CD4
(secondary labelled with Cy2) and counterstained with PI as described in the Materials and methods. Control staining without primary antibodies and isotype
controls are negative. The three figures show first the single fluorescence channels (first column¼AlexaFluor 350; second column¼Cy2) and the last
column shows the overlay of all three channels (blue, red, green).
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Subsequently, we analysed whether Th17 cells can be induced in
HNSCC microenvironment. Supernatants from single cell suspen-
sions of primary tumours as well as lymph node metastasis were
collected 48h after medium exchange and isolated T cells of
healthy donors were incubated for 7 days with these supernatants
(50% HNSCC supernatantþ50% DMEM supplemented with IL-2)
under TCR engagement. Thereafter, the frequency of Th17 cells
was measured by flow cytometry. The T cells stimulated in DMEM
show a statistically significant lower level of Th17 cells
(0.1875%±0.0584) than T cells cultured with tumour supernatants
from the primary tumours and TDLNs (0.8841%±0.136)
(Figure 3B). To verify that the cytokines IL-1b, -6 and -23 are
really the cause for the Th17 cell induction in HNSCC,
we performed the above experiment with blocking antibodies for
IL-1b, -6 and -23. We observed a reduction of the induction of
Th17 cells when incubated with any of these blocking antibodies
and especially for combinations of the antibodies (Figure 3C).
Blocking of IL-1b yields a reduction in Th17 cell induction of
0.39%, blocking of IL-6 one of 0.47% and blocking of IL-23 one of
0.26%. A combination of blocking of the cytokines IL-1b and -6
leads to a reduction of Th17 cell induction of 0.54%, blocking
of IL-1b and -23 one of 0.51% and blocking of IL-6 and -23 one
of 0.42%. Blocking of the cytokines IL-1b, -6 and -23 yields a
reduction of Th17 cell induction of 0.60%. However, the blocking
of all three Th17-inducing cytokines could not abolish the
induction of Th17 cells through HNSCC completely. Therefore,
we investigated whether there are further factors in the tumour
milieu, which lead to the Th17 cell induction. There are reports
that Prostaglandin E2 is also involved in Th17 differentiation;
therefore, we studied the effect of blocking of PGE(2) on Th17 cells
induction in the presence of HNSCC supernatants. With a blocking
antibody for PGE(2), there is a reduced Th17 cell induction
(0.52%±0.082) compared with non-blocked induction (0.89%±
0.136) (Figure 3D). Blocking of IL-1b, -6, -23 and PGE(2) yields the
most prominent decrease of Th17 induction in HNSCC milieu
(0.29%±0.03) (Figure 3D).
Th17 cells migrate towards HNSCC milieu
To test the second hypothesis that Th17 cells maybe able to
migrate directly to tumour site, we performed a migration assay
with a ChemoTx 96 chamber. The wells were filled with 20 10
3
cells of the single cell suspension from tumour or TDLN tissue
suspended in serum-free medium. A total of 20 10
3 Th17 cells
were applied on the top of the filter. After 7h of incubation, we
counted the migrated Th17 cells. We could detect an enhancement
of migration towards the HNSCC filled wells (78 10
2±861
migrated Th17 cells) compared with the DMEM filled wells
(22 10
2±569 migrated Th17 cells) with Po0.01 (Figure 4A).
Owing to the fact that CCR6 is a surface receptor of Th17 cells, we
next analysed whether the migration is CCR6/CCL20 driven.
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Figure 3 Induction of Th17 cells in HNSCC microenvironment. (A) Expression of the Th-17-promoting cytokines IL-1b, -6 and -23 in tumour cells and
TILs ex vivo analysed by flow cytometry. The bars show the mean of the positive cells±s.d. (B) Induction of Th17 cells in HNSCC microenvironment. T cells
were incubated with tumoursupernatants from single cell suspension of tumour tissue for 7 days (n¼30) with Po0.05. The cells were stained with CD3-
FITC, CD4-PerCP, IL-17-APC and analysed by flow cytometry. The data is expressed as the frequency of Th17 cells in the CD4þ T cell population. The
box plots show the median (middle line), 25th and 75th percentiles (box), the extreme values (whiskers, which indicate the 90th and 10th percentile) and
the outliers (circles). (C) Blocking of Th17-inducing cytokines with blocking antibodies diminishes the Th17 induction through HNSCC tumourmilieu. T cells
were incubated with tumoursupernatants from single cell suspension of tumour tissue for 7 days in the presence of blocking antibodies (n¼15). First column
cytokines are not blocked, columns 2–4 block one of the cytokines IL-1b, -6, -23, columns 5–7 block two of the Th17 cell-inducing cytokines, column 8
block all three cytokines. The error bars show the s.d. (D) PGE(2) contributes to Th17 cell induction in HNSCC microenvironment. T cells were incubated
with tumoursupernatants from single cell suspension of tumour tissue for 7 days in the presence of a PGE(2) blocking antibody (n¼15). Blocking of PGE(2)
(column 3) leads to a decrease in Th17 induction in HNSCC milieu. Blocking of IL-1b, -6, -23 and PGE(2) leads to a significant downregulation
of Th17 cells compared with the number of Th17 cells induced through tumour supernatants alone. The error bars show the s.d.
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antibody 30min before the incubation of the migration assay.
We showed a diminished migration of CCR6-blocked Th17 cells
towards the HNSCC cells (21 10
2 migrated Th17 cells) compared
with unblocked Th17 cells (78 10
2±861 migrated Th17 cells)
(Figure 4B).
Th17 inhibits proliferation of HNSCC cells
Next, we considered whether the presence of Th17 cells in tumour
has an impact on tumour growth. We performed an MTT assay to
study the proliferation of tumour cells under the influence of Th17
cells. After 24h incubation of the PCI-13 cells with the Th17 cells
in a transwell chamber, there is an evident attenuation of the
proliferation of HNSCC cells. We have tested different concentration
of Th17 cells (Th17 cells:HNSCC cells 1:1, 5:1, 10:1) (Figure 5A).
The data of the 10:1 and 1:1 concentrations are not shown. We have
repeated this test three times with an eight-fold replication per test.
With all three concentrations, there is a reduction in tumour growth,
which is enhanced with higher concentration.
Concomitantly, we have measured apoptosis and necrosis of the
tumour cells; when incubated together with Th17 cells, we could
detect a statistically significant increase of Annexin V and PI
staining after 24h in tumour cells incubated with Th17 cells (33.0%
Annexin V positive and 10.8% PI positive) vs tumour cells alone
(3.9% Annexin V positive and 6.7% PI positive), whereas the
apoptosis and necrosis in case of the PBMC population without
Th17 cells are significantly lower (10.8% Annexin V positive and
6.8% PI positive) with Po0.05 (Figure 5B). To examine whether
these proliferation decrease is cell–cell contact dependent, we
repeated the proliferation assay with Th17 supernatants instead of
Th17 cells and found that the proliferation is still decreased
compared with the proliferation of tumour cells alone, but not as
potent as with Th17 cells (Figure 5D). The proliferation inhibition
cannot be completely abolished with an IL-17 blocking antibody
(data not shown).
Tumour cells express the receptor for IL-17, -21 and -22
Next, we determined by flow cytometry if HNSCC can generally
trigger a response to the cytokines secreted by Th17 cells (IL-17, -21
and -22) by expression of the corresponding cytokine receptors of
the Th17 cell cytokines (IL-17R, -21R, -22R). We were not able to
analyse the IL-26R because of the lack of an appropriate antibody.
All tumour cells we have investigated bear the receptors for the
Th17 cell cytokines. The IL-17R was found in 93.8±10.2% of
tumour cells, IL-21R in 36.7±7.6% and IL-22R in 27.7±9.5%
(Figure 5C).
Th17 cells compromise the angiogenesis of HNSCC
We analysed whether Th17 cells influence the angiogenesis of
HNSCCs. Therefore, we performed a proteome profiler human
angiogenesis array to measure the expression of angiogenesis-
related molecules in HNSCC in the presence of Th17 cells
compared with HNSCC alone. We incubated the HNSCC cell line
PCI-13 for 24h with Th17 cells (concentration 1:1) in a transwell
chamber and isolated the protein of the tumour cells. We observed
an upregulation of most angiogenesis-promoting factors and a
downregulation of most angiogenesis-inhibiting factors for the
HNSCC cells incubated with Th17 cells compared with HNSCC
cells alone (Figure 6).
DISCUSSION
Less is known about the function of Th17 cells in cancer (Bronte,
2008; Zhang et al, 2008a), especially in head and neck cancer.
It was shown that Th17 cells are involved in tissue inflammation
through the induction of the release of the cytokines IL-8, -6,
COX-2, MMP-1, -3, CXCL1 NOS-2 by surrounding cells such
as fibroblasts, macrophages, endothelial and epithelial cells
(Brennan et al, 2001; Agarwal et al, 2008; Gu et al, 2008), which
are involved in angiogenesis, tumour invasion and metastasis
(Brennan et al, 2001; Nabeshima et al, 2002; Li et al, 2003;
Wei et al, 2003). On this account, it is reasonable to propose an
impact of Th17 cells on cancer progression and pathogenesis.
In ovarian cancer, it was shown that Th17 cells are increased in
tumour tissue, but not in peripheral blood (Miyahara et al, 2008;
Zhang et al, 2008a); in gastric cancer, there was both an elevation
of Th17 frequency in peripheral blood and TDLNs. But nothing
functional is known about Th17 cells and their influence on
cancer development in human beings. The aim of our study was to
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Figure 4 The Th17 cells migrate towards HNSCC milieu. (A) Migration
assay with the ChemoTx Sytem as described in Materials and methods. In the
wells of the 96-well plate, 20 10
3 HNSCC cells of the cell line PCI-13 were
seeded and on the top of the filter 20 10
3 Th17 cells. After 8h of
incubation, the cells in the well of the 96-well plate were harvested and
stained with CD3-FITC, CD4-PerCP, IL-17-APC and analysed with flow
cytometry. The first column shows the migration of Th17 cells vs DMEM, the
second column shows the migration of Th17 cells vs HNSCC cells (n¼25)
with Po0.05. The box plots show the median (middle line), 25th and 75th
percentiles (box), the extreme values (whiskers, which indicate the 90th and
10th percentile) and the outliers (circles). (B)T h em i g r a t i o no fT h 1 7c e l l s
towards tumour is CCR6/CCL20 dependent. The Th17 cells were incubated
with CCR6 blocking antibody. In the chemotaxis assay, these blocked Th17
cells (column 3) show a reduced migration towards HNSCC compared with
the unblocked Th17 cells (column 2) (n¼15) with Po0.05.
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sanalyse the function of Th17 cells in cancer pathogenesis of
HNSCC. First, we studied the frequencies of Th17 cells in
peripheral blood, tumour and TDLN tissue of HNSCC patients.
We could identify a higher percentage of Th17 cells in peripheral
blood of head and neck patients compared with healthy controls.
We could not identify any relationship between TNM staging
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Figure 5 The proliferation of HNSCC cells is reduced in the presence of Th17 cells. (A) PCI-13 cells were incubated with Th17 cells, Th1 cells and
DMEM in a transwell chamber over 96h and the cell number was checked every 24h with MTT reagents. The lines are the mean of eight-fold repeats±s.d.
(B) The HNSCC cell line PCI-13 were incubated with Th17 cells, Th17-depleted PBMCs and DMEM, and after 24h of incubation, the PCI-13 cells were
harvested and stained with Annexin and PI and analysed by flow cytometry. The HNSCC cells incubated with Th17 cells show a significant upregulation of
Annexin V as well as PI (n¼15). The bars show the mean of the positive cells±s.d. with Po0.05. (C) Expression of IL-17R (first bar), IL-21R (second bar)
and IL-22R (third bar) on tumour cells analysed by flow cytometry. The bars show the mean of eight-fold repeats±s.d. (D) PCI-13 cells were incubated with
Th17 cells, Th17 cell supernatant and DMEM over 96h and the tumour cell number was checked every 24h with MTT reagents. The lines are the mean of
eight-fold repeats±s.d.
HNSCC
Angiogenesis inducers Angiogenesis inhibitors
MMP-8 o Coagulation factor  + Vasohibin  –
MMP-9 + Endothelin + IGFBP-1 o
uPA + Endoglin  + IGFBP-2 o
VEGF + DPP IV + IGFBP-3 –
VEGF-C + Artemin  – Endostatin –
HNSCC incubated with Th17 cells
NRG-1-1 – Angiogenin + Activin A o
Leptin – Angiopoetin-1 – AdamTS-1 o
PD-ECGF + Angiopoetin-2 o Angiostatin –
PDGF-AA + CXCL-16 + Amphiregulin –
PDGF-AB/PDGF-BB + FGF-acidic + PTX-3 –
IL-1 o FGF-basic  + Persephin  –
IL-8 + FGF-4 + Platelet Factor 4 o
GDNF – FGF-7 + Prolactin  o
GM-CSF + PIGF o Serpin b5 o
EG-VEGF + Serpin e1 o
EGF + Serpin f1 –
HB-EGF + TIMP1 +
HGF + TIMP4 –
TGF- – Thrombospondin 1 o
MCP-1 o Thrombospondin 2 –
Figure 6 The angiogenesis of HNSCC is impaired in the presence of Th17 cells. Table of the angiogenesis-related proteins spotted on the angiogenesis
array. For the angiognesis profiler array, HNSCC cells were incubated over 48h with or without Th17 cells over 48h. The protein of the HNSCC cells were
then isolated and incubated with the antibody spotted membrane of the angiogenesis array. The first and second columns are the angiogenesis inducers,
the third column is the angiogenesis inhibitors (þ, upregulation of expression after incubation with Th17 cells; o, no change;  , downregulation of
expression).
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sand Th17 cell frequency, so our conclusion is that Th17 cells
were consistently elevated in HNSCC patients independent of
tumour stage. In addition, all primary tumours except larynx
carcinomas and particularly TDLNs are infiltrated by a high
number of Th17 cells, whereas TDLNs show a significant higher
frequency of Th17 cells than primary tumours. This matter of
fact may represent an additional link between the interrelationship
of inflammation and cancer, but the exact mechanism of
how these high amount of proinflammatory Th17 cells and the
therewith connected secreted cytokines contribute to the inflam-
matory processes in cancer remain to be elucidated. In this article,
we report that Th17 cells can be induced through HNSCC
supernatants. After incubation of isolated naive CD4þ T cells in
head and neck cancer milieu in vitro, we could detect a significant
elevated number of Th17 cells. We propose that HNSCC
microenvironment is, therefore, able to induce Th17 lineage
commitment. The HNSCC is a Th17-promoting milieu because of
the release of IL-23 and -6 by the tumour cells itself and by TILs
and IL-1b by tumour-infiltrating immune cells. The IL-1b and -6
are required to induce Th17 induction and IL-23 is necessary
for the expansion of Th17 cells. We suggest that PGE(2) is a major
inducer for Th17 cells in HNSCC microenvironment. We had not
examined the amount of PGE(2) in HNSCC tissue, but it is
well known that the prostaglandin biosynthesis is impaired in
HNSCC, and PGE(2) is highly overexpressed (Camacho et al,
2008). Owing to the fact that it was shown that PGE(2) leads to
Th17 expansion (Chizzolini et al, 2008) and that PGE(2) leading
to a rapid increase of RORgt and the selective enrichment of
IL-17-producing cells by modulating the proliferation of
memory T cells (Napolitani et al, 2009), we could show that
PGE(2) levels in HNSCC lead to a strong enhancement of Th17 cell
expansion directly at the tumour site and in TDLNs. Next,
we found that Th17/Th1 cells were seriously downregulated
both in peripheral blood as well as in tumour tissue and TDLNs.
It is known that Th1 cytokines are diminished in HNSCC
(Bose et al, 2008). The IFNg can also be downregulated
by TCR triggering in the presence of PGE(2) in memory T cells
(Napolitani et al, 2009), whereas IL-17 is upregulated, so this
maybe the responsible mechanism for the Th17 and Th1/Th17
cell modulation in HNSCC. But the issue remains what happens
with this Th17/Th1 cells under tumour influence, if they
simply attenuate IFNg secretion or change into another T cell
population. Our hypothesis is that Th17 cells were functionally
modulated by tumour milieu and were converted into Th1 cells.
We could reveal in this article that tumour cells bear all cytokine
receptors IL-17R, -21R, -22R necessary to respond on the
proinflammaory cytokines secreted by Th17 cells (except IL-26R,
which we have not measured), so we propose that tumour
cells can be massively influenced by surrounding tumour-
infiltrating Th17 cells. Next, we addressed the issue whether
Th17 have any functional implications on HNSCC development
and HNSCC milieu. First, we analysed whether Th17 cells are able
to influence tumour proliferation or even lead to apoptosis of
tumour cells. So far, only the influences of the single cytokines
from Th17 cells on cancer development were investigated in
human beings, but nothing is known about the combinations
of neither the Th17 cytokines nor the Th17 cells. There are
different reports about the influence of IL-17 on tumour
progression, some depict a positive influence of Th17 on tumour
proliferation (Benchetrit et al, 2002; Numasaki et al, 2005) and
angiogenesis, whereas others describe a inhibitory influence on
tumour growth (Nam et al, 2008; Kryczek et al, 2009). Muranski
et al (2008) report that Th17 cells in a mouse model are able
to eradicate melanomas. Ciree et al (2004) show that IL-17
is upregulated in the T cell lymphomas mycosis fungoides and
Sezary syndrome and may act as a tumour growth-promoting
or -inhibiting factor. In addition, they show an association between
IL-17 expression and polymorphonuclear neutrophil infiltration.
This association was affirmed by Garcia-Hernandez Mde et al
(2010); they describe that neutrophils were attracted to the tumour
milieu by an IL-17-dependent mechanism and show that depletion
of neutrophils resulted in a diminished capacity to control tumour
growth. In addition, Honorati et al (2003) report a increased
susceptibility of osteosarcoma cells to NK cell lysis under the
influence of IL-17. The effects of IL-21 on tumour development are
discussed controversially. It was shown that IL-21 not only
promotes tumour growth (Menoret et al, 2008), but also acts
anti-tumourally and inhibited tumour angiogenesis (Castermans
et al, 2008), enhances antibody-mediated tumour rejection (Smyth
et al, 2008) and activates NK cells and CD8þ T cells. Opposing
views are reported about the regulation of Tregs by IL-21.
Lamprecht et al (2008) propose an increase of the number of
Tregs within tumour microenvironment by inducing CCL20
and therewith the migration of Tregs towards tumour, whereas
Kim-Schulze et al (2009) revealed a reduction of Tregs through
IL-21. Less is known about the function of IL-22 in tumour
pathogenesis. Zhang et al (2008b) report that autocrine IL-22 has
an antiapototic activity in human lung cancer, whereas Weber et al
(2006) describe an inhibitory effect of IL-22 on signalling pathways
promoting cell proliferation. There is no existing data about IL-26
in cancer. In this study, we assessed reduced tumour growth of a
head and neck cancer cell line in the presence of different numbers
of Th17 cells, whereas there is an induction of pro-angiogenetic
factors in tumour cells in the presence of Th17 cells. The decrease
of tumour cell proliferation is cell contact dependent because Th17
cell supernatants cannot inhibit the proliferation of HNSCC cells as
Th17 cells can inhibit it. But probably there exist a concentration
dependency, because we could detect such a dependency in
proliferation assay using the cytokine IL-17 (data not shown).
We observed a reduced tumour growth with low concentrations of
IL-17 and an increase in proliferation with concentrations above
1pgml
–1. Maybe a certain threshold level is needed for tumour
cells to use IL-17 for their benefit. In this study, we report that
Th17 cells are able to migrate towards HNSCC milieu. We showed
that this migration is CCR6/CCL20 driven. It was shown that Th17
cells express CCR6, which enables them to migrate inflamed tissue
in response to CCL20. In addition, they express the CCR6 ligand
CCL20, though CCL20 from Th17 cells in turn promotes the
migration of other Th17 cells (Yamazaki et al, 2008). It was shown
that different tumour entities overexpress the chemokine CCL20
(Rubie et al, 2006a,b) and that the serum levels of patients with
nasopharyngeal carcinomas are elevated. In addition, it is
established that metastases express more CCL20 than primary
tumours (Rubie et al, 2006b), so this could be the explanation for
the fact that we could measure a higher amount of Th17 cells in
lymph node metastasis than in primary tumours. Su et al (2010)
describe that RANTES and MCP-1 secreted in tumour milieu
mediate the recruitment of Th17 cells. In addition, they find that
tumour cells and tumour-derived fibroblasts produce a cytokine
milieu as well as provide cell–cell contact engagement that
facilitates the generation of Th17 cells.
Altogether, we showed for the first time that Th17 cells are
present to a high amount in HNSCCs. In addition, Th17 cells were
induced through factors in tumour milieu and actively migrate
towards tumour milieu and have a potent impact on carcinogen-
esis of head and neck cancers. However, it is similar to an double-
edged sword, on the one side Th17 cells seem to be beneficial to the
host because of their proliferation reducing activity, on the other
side they accelerate metastasis through the induction of angiogen-
esis and seem, therefore, beneficial to tumour. Therefore, it is
important to study the function of Th17 cells in malignant diseases
in depth and try to elucidate their mechanism of action and their
modulation by tumour microenvironment to find a possibility how
Th17 cells have to be modulated that they are beneficial for tumour
patients. Our results raise several further issues to investigate –
first, whether Th17 cells express different molecules or secrete
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sdifferent cytokines in HNSCC patients compared with healthy
persons. Eventually, it has to be investigated in future whether
Th17 cells can recognise tumour cells and if they are at all able to
impair tumour growth or metastasis in vivo and if they do so, one
has to elucidate the exact mechanism of action. Another open
question is whether HNSCC is able to modulate Th17 function for
immune escape.
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